

**S3 Table.** Factors associated with progression-free survival and overall survival

Variable	Progression-free survival				Overall survival			
	Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age $\geq$ 80 yr	1.81 (1.04-3.14)	0.036	1.67 (0.92-3.02)	0.092	1.92 (1.04-3.53)	0.037	1.50 (0.74-3.03)	0.259
Male sex	0.99 (0.61-1.59)	0.956	0.94 (0.55-1.58)	0.798	1.02 (0.61-1.70)	0.948	0.93 (0.53-1.65)	0.813
Recurrent disease (vs. initially metastatic)	0.76 (0.48-1.19)	0.223	-	-	0.56 (0.35-0.91)	0.019	0.64 (0.37-1.10)	0.109
ECOG PS $\geq$ 2	1.83 (1.15-2.92)	0.010	1.51 (0.91-2.53)	0.113	2.49 (1.53-4.06)	< 0.001	2.09 (1.22-3.57)	0.007
Diabetes mellitus	1.54 (0.93-2.56)	0.095			1.25 (0.73-2.15)	0.420		
Hypertension	1.12 (0.72-1.73)	0.620			0.94 (0.59-1.50)	0.803		
Bladder primary	1.03 (0.67-1.60)	0.893	-	-	1.13 (0.71-1.78)	0.613		
Lymph node metastasis	0.91 (0.59-1.42)	0.679	-	-	1.21 (0.76-1.93)	0.430	-	-
Visceral metastasis	1.76 (1.12-2.75)	0.013	1.42 (0.85-2.37)	0.178	1.60 (1.00-2.56)	0.049	1.06 (0.62-1.82)	0.822
RDI of gemcitabine <sup>a)</sup> < median	2.21 (1.41-3.46)	0.001	1.22 (0.68-2.18)	0.514	3.03 (1.87-4.90)	< 0.001	1.75 (0.93-3.29)	0.081
RDI of carboplatin <sup>a)</sup> < median	2.22 (1.38-3.58)	0.001	1.43 (0.78-2.60)	0.247	3.22 (1.94-5.36)	< 0.001	1.80 (0.96-3.40)	0.069
eGFR < 30 mL/min	3.03 (1.74-5.27)	< 0.001	2.57 (1.42-4.65)	0.002	3.26 (1.83-5.82)	< 0.001	2.94 (1.57-5.54)	< 0.001

CI, confidence interval; Eastern Cooperative Oncology Group; ECOG PS, Eastern Cooperative Oncology Group performance status; eGFR, estimated glomerular filtration rate; HR, hazard ratio; PS, performance status; RDI, relative dose intensity. <sup>a)</sup>RDI was calculated for the first two cycles (i.e., cycles 1 and 2).